William Jacob Savage Sells 13,093 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 13,093 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the transaction, the insider owned 75,702 shares of the company’s stock, valued at approximately $6,905,536.44. This trade represents a 14.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Disc Medicine Stock Down 4.5%

NASDAQ IRON opened at $87.35 on Thursday. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $99.50. The company has a market capitalization of $3.30 billion, a P/E ratio of -16.33 and a beta of 0.87. The company’s 50 day simple moving average is $87.33 and its 200 day simple moving average is $68.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). Equities research analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. acquired a new stake in Disc Medicine during the first quarter valued at $78,288,000. Siren L.L.C. purchased a new stake in shares of Disc Medicine during the 1st quarter worth about $53,207,000. Wellington Management Group LLP raised its stake in shares of Disc Medicine by 67.9% during the 1st quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company’s stock worth $116,331,000 after purchasing an additional 948,094 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Disc Medicine by 257.1% during the 3rd quarter. Vestal Point Capital LP now owns 500,000 shares of the company’s stock valued at $33,040,000 after buying an additional 360,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $22,342,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $117.00 target price on shares of Disc Medicine in a report on Monday, December 8th. Morgan Stanley boosted their price objective on Disc Medicine from $90.00 to $115.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a report on Tuesday. Wedbush boosted their price target on shares of Disc Medicine from $90.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Finally, Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $132.00 to $153.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $119.00.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.